These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 36265326)

  • 21. Accessing opioid agonist treatment in prison in England and Scotland remains problematic - the views of people with lived experience.
    Webster R; Fearns C; Harriott P; Millar L; Simpson J; Wallace J; Wheatley M
    Int J Prison Health (2024); 2024 May; 20(2):143-155. PubMed ID: 38984599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder.
    Gottlieb DJ; Shiner B; Hoyt JE; Riblet NB; Peltzman T; Teja N; Watts BV
    Acta Psychiatr Scand; 2023 Jan; 147(1):6-15. PubMed ID: 35837885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales.
    Strang J; Sheridan J; Hunt C; Kerr B; Gerada C; Pringle M
    Br J Gen Pract; 2005 Jun; 55(515):444-51. PubMed ID: 15970068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
    Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
    JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global opioid agonist treatment: a review of clinical practices by country.
    Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
    Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia.
    Bazazi AR; Culbert GJ; Wegman MP; Heimer R; Kamarulzaman A; Altice FL
    BMC Infect Dis; 2022 Nov; 22(1):837. PubMed ID: 36368939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
    Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
    Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incremental expenditures attributable to daily dispensation and witnessed ingestion for opioid agonist treatment in British Columbia: 2014-20.
    Nosyk B; Kurz M; Guerra-Alejos BC; Piske M; Dale L; Min JE
    Addiction; 2023 Jul; 118(7):1376-1380. PubMed ID: 36772838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences.
    McDonald R; Bech AB; Clausen T
    BMC Health Serv Res; 2023 Sep; 23(1):965. PubMed ID: 37679751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non drug-related and opioid-specific causes of 3262 deaths in Scotland's methadone-prescription clients, 2009-2015.
    Gao L; Robertson JR; Bird SM
    Drug Alcohol Depend; 2019 Apr; 197():262-270. PubMed ID: 30875647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic.
    Tanz LJ; Jones CM; Davis NL; Compton WM; Baldwin GT; Han B; Volkow ND
    JAMA Netw Open; 2023 Jan; 6(1):e2251856. PubMed ID: 36662523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
    Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
    Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022.
    Bharat C; Chidwick K; Gisev N; Farrell M; Ali R; Degenhardt L
    Int J Drug Policy; 2024 Jan; 123():104255. PubMed ID: 38029481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study.
    Bech AB; Clausen T; Waal H; Šaltytė Benth J; Skeie I
    BMC Health Serv Res; 2019 Jul; 19(1):440. PubMed ID: 31266495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy.
    Johnson S; Martin PR
    Am J Drug Alcohol Abuse; 2018; 44(3):310-316. PubMed ID: 28829626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.